Keywords:
Kidney, CT, Contrast agent-intravenous, Cancer
Authors:
X. Shen1, L. Zhou2, L. Cheng2; 1Shen Zhen/CN, 2shenzhen/CN
DOI:
10.1594/ecr2018/C-1349
Methods and materials
Twenty eight patients with histologically proven renal oncocytomas (6),
LPAML (8),
PRCC (8) and ChRCC(6) were included.
All patients underwent 128-slice CT examinations with plain and three contrast-enhanced phases.
Imaging findings of these patients were retrospectively analyzed by 2 board certified radiologists.
Lesion homogeneity,
presence/absence of tumor necrosis,
central scars,
tumor vessels and enhancement kinetics were evaluated.
The differences of CT values of the tumours between three contrast-enhanced phases and plain scan were calculated and recorded; differences of tumor CT values between corticomedullary phase and plain scan (∆CT1*); between parenchyma phase and plain scan (∆CT2*); between excretory phase and plain scan (∆CT3*).
Changes in CT value between 20-40HU were considered mild enhancement; 40-80HU moderate enhancement and more than 80HU distinct enhancement.
The range and location of region of interest (ROI) of each lesion were same on plain and three contrast-enhanced phases.
Comparison among the ∆CT of all patients was made using multivariate analysis of variance (MANOVA).